1. Home
  2. DFLI vs TVGN Comparison

DFLI vs TVGN Comparison

Compare DFLI & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$1.52

Market Cap

25.1M

Sector

Technology

ML Signal

HOLD

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

HOLD

Current Price

$3.64

Market Cap

21.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
TVGN
Founded
2020
2020
Country
United States
United States
Employees
141
18
Industry
Electronic Components
Blank Checks
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
21.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DFLI
TVGN
Price
$1.52
$3.64
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$3.25
N/A
AVG Volume (30 Days)
297.5K
18.6K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.14
52 Week High
$5.15
$12.03

Technical Indicators

Market Signals
Indicator
DFLI
TVGN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DFLI
TVGN

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: